BC
OLMA icon

Boxer Capital’s Olema Pharmaceuticals OLMA Stock Holding History

Boxer Capital’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-650,000
Closed -$7.76M – 37
2024
Q3 		$7.76M Hold
650,000
– – 0.38% 45
2024
Q2 		$7.03M Buy
+650,000
New +$7.05M 0.37% 46

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return

Boxer Capital's OLMA Position: Q4 2024 in Review

Boxer Capital sold out of Olema Pharmaceuticals (OLMA) in Q4 2024, closing a stake of 650,000 shares — an estimated $7.76M sold.

Boxer Capital first reported a position in OLMA in Q2 2024 and held it in 2 quarters. The position peaked at $7.76M in Q3 2024. 156 funds tracked by Wall St. Rank hold OLMA as of Q4 2024.

  • Boxer Capital reported no remaining Olema Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Boxer Capital sold 650,000 Olema Pharmaceuticals shares in Q4 2024, an estimated $7.76M.
  • Boxer Capital first reported a position in Olema Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Boxer Capital's Olema Pharmaceuticals position peaked at $7.76M in Q3 2024.
  • 156 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.